Prevalence Of Potential Antibody Drug Conjugate (ADC) Targets With PD-L1 In Breast Cancer And Lung Cancer Patients With Clinical Response Information
Time: 1:00 pm
day: Conference Day One
Details:
- Breast and Lung cancer are important diseases for antibody drug conjugate (ADC) therapeutic development with several approved in both diseases
- Tristar ran approved IHC assays for HER2 and PD-L1 and optimized IHC assays for TROP2, NECTIN-4, B7-H3, and B7-H4 on serial slides from tissue microarrays for breast (hormone receptor positive) and non-small cell lung cancer (adeno and squamous subtypes)
- Pathologists scored each target on the plasma membrane using approved methods for HER2 and PD-L1 and digital image analysis for percentage of tumor cells at varying intensities expressing other ADC targets. Summary data for prevalence of each target will be presented. The data may help inform where these ADC targets are highest expressed, where they overlap with respect to each other, and how expression correlates to standard of care outcomes data and their potential for combining with immunotherapies.
